KeyBank National Association
APLS

KeyBank National Association’s Apellis Pharmaceuticals APLS Stock Holding History

KeyBank National Association’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,084
Closed -$206K – 1193
2025
Q3 		$206K Buy
+9,084
New +$212K ﹤0.01% 1131
2024
Q3 		– Sell
-7,449
Closed -$286K – 1131
2024
Q2 		$286K Buy
7,449
+879
+13% +$39.8K ﹤0.01% 946
2024
Q1 		$386K Buy
6,570
+21
+0.3% +$1.34K ﹤0.01% 853
2023
Q4 		$392K Buy
+6,549
New +$332K ﹤0.01% 844
2023
Q2 		– Sell
-8,373
Closed -$552K – 1055
2023
Q1 		$552K Hold
8,373
– – ﹤0.01% 658
2022
Q4 		$433K Hold
8,373
– – ﹤0.01% 743
2022
Q3 		$572K Hold
8,373
– – ﹤0.01% 603
2022
Q2 		$379K Buy
+8,373
New +$382K ﹤0.01% 788

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

KeyBank National Association's APLS Position: Q4 2025 in Review

KeyBank National Association sold out of Apellis Pharmaceuticals (APLS) in Q4 2025, closing a stake of 9,084 shares — an estimated $206K sold.

KeyBank National Association first reported a position in APLS in Q2 2022 and held it in 8 quarters. The position peaked at $572K in Q3 2022. 279 funds tracked by Wall St. Rank hold APLS as of Q4 2025.

  • KeyBank National Association reported no remaining Apellis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • KeyBank National Association sold 9,084 Apellis Pharmaceuticals shares in Q4 2025, an estimated $206K.
  • KeyBank National Association first reported a position in Apellis Pharmaceuticals in Q2 2022 and held it in 8 quarters.
  • KeyBank National Association's Apellis Pharmaceuticals position peaked at $572K in Q3 2022.
  • 279 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2025.

Based on KeyBank National Association's 13F filing for Q4 2025, filed 30 Jan 2026.